Weekly Recap: REGENXBIO and UPenn settlement and $39M payment to Regenxbio
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) paid $39M to settle patent suits with REGENXBIO and UPenn, securing releases and AAVrh74/ELEVIDYS covenants and dismissing litigation, while preparing late—breaking ELEVIDYS efficacy/safety data and multiple posters, including Phase 4 ENDURE results, for upc…
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) paid $39M to settle patent suits with REGENXBIO and UPenn, securing releases and AAVrh74/ELEVIDYS covenants and dismissing litigation, while preparing late—breaking ELEVIDYS efficacy/safety data and multiple posters, including Phase 4 ENDURE results, for upc…